araag2/HINT huggingface dataset:
Clinical trial NCT01688037 (phase 2, status: completed)
Conditions: tardive dyskinesia
ICD codes: K22.4, G24.01
Drugs: nbi-98854, nbi-98854, placebo
SMILES: COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1, COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a clinical diagnosis of schizophrenia or schizoaffective disorder and a clinical
             diagnosis of neuroleptic-induced tardive dyskinesia for at least 3 months prior to
             screening.

          -  Be receiving a stable dose of antipsychotic medication for a minimum of 30 days before
             study start. Subjects who are not using antipsychotic medication must have stable
             psychiatric status.

          -  Have the doses of concurrent medications and the conditions being treated be stable
             for a minimum of 30 days before study start and be expected to remain stable during
             the study.

          -  Subjects of childbearing potential must agree to use hormonal or two forms of
             nonhormonal birth control during the study.

          -  Female subjects must not be pregnant.

          -  Be in good general health and expected to complete the clinical study as designed.

          -  Have a body mass index (BMI) of 18 to 38 kg/m2 (both inclusive).

          -  Have a negative urine drug screen (negative for amphetamines, barbiturates,
             benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids) at screening and
             study start, except for any subject receiving a stable dose of benzodiazepine.

          -  Have a negative alcohol breath test at screening and study start.

        Exclusion Criteria:

          -  Have an active clinically significant unstable medical condition within 1 month (30
             days) prior to screening.

          -  Have a history of substance dependence or substance (drug) or alcohol abuse within the
             3 months before study start(nicotine and caffeine dependence are not exclusionary).

          -  Have a known history of neuroleptic malignant syndrome.

          -  Have a significant risk of suicidal or violent behavior.

          -  Receiving any excluded concomitant medication such as reserpine, metoclopramide,
             stimulants, or tetrabenazine.

          -  Receiving medication for the treatment of tardive dyskinesia.

          -  Have a positive human immunodeficiency virus antibody, (HIV-Ab), hepatitis B surface
             antigen (HBsAg), or hepatitis C virus (HCV) antibody result at screening or have a
             history of positive result.

          -  Have received an investigational drug within 30 days before screening or plan to use
             an investigational drug (other than NBI-98854) during the study.

          -  Have an allergy, hypersensitivity, or intolerance to tetrabenazine.

          -  Have had previous exposure with NBI-98854.
Clinical trial NCT00726323 (phase 2, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: foretinib (formerly gsk1363089 or xl880)
SMILES: COC1=C(OCCCN2CCOCC2)C=C2N=CC=C(OC3=C(F)C=C(C=C3)N=C(O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of PRC with metastatic disease or bilateral
             multifocal renal tumors localized to kidneys. Measurable disease, ECOG performance
             status of </= 2.

          -  Adequate bone marrow reserve, hepatic, renal, and cardiovascular function.

        Exclusion Criteria:

          -  Radiation to >/=25% of bone marrow within 14 days of GSK1363089, more than 1 prior
             anti-cancer therapy, received prior treatment with a c-met inhibitor, brain
             metastases,

          -  Any uncontrolled intercurrent illness,

          -  Pregnant or breastfeeding,

          -  HIV positive
Clinical trial NCT01037478 (phase 2, status: completed)
Conditions: hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: resminostat (4sc-201)
SMILES: CN(C)CC1=CC=C(C=C1)S(=O)(=O)N1C=CC(\C=C\C(=O)NO)=C1
Eligibility criteria:

        Main Inclusion Criteria:

          -  Patients must have histological or cytological evidence of Hodgkin's Lymphoma (all
             subtypes are acceptable)

          -  Patients must have relapsed or refractory Hodgkin's Lymphoma (HL) defined as relapse
             following initial therapy or lack of response to first line therapy and treatment with
             second-line (salvage therapy). Patients may have also undergone high-dose chemotherapy
             with autologous stem cell transplantation at least 12 weeks prior to study entry

          -  Patients must have measurable anatomical disease present on CT scan

          -  Patients must have an ECOG Performance Score of 0, 1 or 2

        Main Exclusion Criteria:

          -  Patients who have received previous treatment with an HDAC inhibitor

          -  Patients who have undergone allogeneic hematopoietic stem cell transplantation

          -  Patients with known or suspected involvement of the CNS by HL

          -  Patients treated with agents known to prolong the QT interval or with a confirmed QTcF
             > 450 msec

          -  Patients with a history of other malignancies unless having undergone definitive
             treatment more than 5 years prior to entry into the study and without evidence of
             recurrent malignant disease, excluding patients with basal cell carcinoma of the skin;
             superficial carcinoma of the bladder; carcinoma of the prostate with a current PSA <
             0.1 ng/ml; or cervical intraepithelial neoplasia

          -  Patients with a history of significant cardiovascular, neurological, endocrine,
             gastrointestinal, respiratory or inflammatory illness that could preclude their
             participation in the trial, pose an undue medical hazard or interfere with the
             interpretation of the trial results, including, but not limited to, patients with
             congestive heart failure (NYHA Class 3 or 4); unstable angina; cardiac arrhythmia;
             recent (within the preceding 6 months) myocardial infarction or stroke; hypertension
             requiring > 2 medications for adequate control; diabetes mellitus with > 2 episodes of
             ketoacidosis in the preceding 12 months
Clinical trial NCT00421317 (phase 2, status: terminated)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: imatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Reason stopped: 
    study stopped at the end of the first step
  
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic ocular melanoma

          -  Age > or = 18 years old

          -  Measurable metastases > or = 10 mm according to RECIST criteria

          -  PS-WHO < or = 1 or IK > 70 percent

          -  Normal hepatic function

          -  PNN > 1500/mm3, platelets > or = 100 000/mm3

          -  Contraception

          -  Informed consent signed

        Exclusion Criteria:

          -  Patient with two prior lines of systemic treatment (chemotherapy, immunotherapy or
             association)

          -  Other evolutive neoplasic disease

          -  Severe hepatic insufficiency

          -  Severe renal insufficiency

          -  Somatic or psychiatric co-morbidity incompatible with the protocol

          -  Leptomeningeal or cerebral metastatic dissemination

          -  Pregnant or lactating woman

          -  Other antitumoral treatment

          -  Patient participating to another clinical trial with an experimental drug

          -  Known hypersensitivity to Imatinib or one of its excipients

          -  Resecable single metastasis
Clinical trial NCT01582815 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: jnj-40411813, placebo
SMILES: CCCCN1C=CC(N2CCC(CC2)C2=CC=CC=C2)=C(Cl)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Major Depressive Disorder (MDD); patients with a diagnosis of comorbid
             Generalized Anxiety Disorder, Social Anxiety Disorder, or Panic Disorder may be
             included, if the investigator considers MDD to be the primary diagnosis

          -  A 17-item Hamilton Depression Rating Scale (HDRS17) total score =>18

          -  A HDRS17 anxiety/somatization factor score =>7

          -  Is receiving an antidepressant

        Exclusion Criteria:

          -  Has other psychiatric condition, including, but not limited to, MDD with psychotic
             features, bipolar disorder, obsessive-compulsive disorder, post-traumatic stress
             disorder, borderline personality disorder, eating disorder, or schizophrenia

          -  Has a length of current Major Depressive Episode (MDE) >6 months

          -  Has a current or recent history of clinically significant suicidal ideation within the
             past 6 months, or a history of suicidal behavior within the past year

          -  Not including the inadequate response to the current antidepressant, has more than 1
             failed antidepressant treatment of adequate dose and duration in the current MDE
Clinical trial NCT01038804 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ym155, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically- or cytologically-proven adenocarcinoma of the breast that is HER2
             negative. Subjects with hormone receptor positive or negative status are eligible.
             Additionally, subjects with triple negative status (meaning estrogen receptor
             negative, progesterone receptor negative and HER2 negative) are eligible

          -  No prior chemotherapy regimen for metastatic breast cancer

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 at the Baseline Visit

          -  The subject's life expectancy is estimated to be > 12 weeks at the Baseline Visit

          -  The subject must be non-pregnant and non-lactating. All sexually active subjects of
             childbearing potential must agree to use an adequate method of contraception
             throughout the study period

        Exclusion Criteria:

          -  Hypersensitivity to docetaxel or polysorbate 80

          -  Neuropathy ≥ Grade 2 at the Baseline Visit

          -  Known brain or leptomeningeal metastasis as assessed through medical history review
             and physical examination

          -  The subject has known Human Immunodeficiency Virus (HIV), Hepatitis B surface Antigen
             or hepatitis C antibody
Clinical trial NCT00555477 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: anastrozole
SMILES: CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Reason stopped: 
    the study was stopped after 69 subjects were enrolled because of poor accrual.
  
Eligibility criteria:

        Inclusion Criteria:

        To be eligible for this study:

          1. You must be at least 18 years of age and not older than 60 years of age

          2. You have breast cancer which was confined to the breast and lymph nodes under the arm,
             and have no evidence of cancer elsewhere

          3. You must have had surgical removal of your tumor, and if indicated, radiation therapy
             must have been completed or planned

          4. Your tumor must express estrogen and/or progesterone receptors

          5. You must have had a menstrual period within 6 months before starting chemotherapy for
             your breast cancer.

          6. You must have been treated with a chemotherapy regimen that includes cyclophosphamide
             (Cytoxan). Your menstrual periods must have stopped for at least 8 weeks starting
             during or after chemotherapy.

        Exclusion Criteria:

        You are not eligible to participate in this study if:

        1. Your ovaries have been surgically removed, treated with radiation therapy, or if you are
        taking medications (Zoladex™ or Lupron™) to block the function of your ovaries.
Clinical trial NCT01392560 (phase 2, status: completed)
Conditions: diabetes mellitus, type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: bi 10773
SMILES: [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1
Eligibility criteria:

        Inclusion criteria:

          1. Male or female subjects 18 years of age or older diagnosed with type 1 diabetes
             mellitus

          2. Glycated hemoglobin (HbA1C) of 6.5% to 11.0% and an estimated glomerular filtration
             rate (eGFR) greater or equal to 60 ml/min/1.73m² at screening

          3. Subjects must be either experienced insulin pump users or be on multiple daily
             injections of any type of insulin

        Exclusion criteria:

          1. Evidence of macroalbuminuria or leukocyte positive urinalysis at screening

          2. Any concomitant medication known to interfere with renin-angiotensin-aldosterone
             system (RAAS) activity or treatment with any other drugs to reduce blood glucose other
             than insulin

          3. History of macrovascular disease or any other disease which would interfere with trial
             participation or any ongoing clinical condition that would jeopardize subject safety
             or study compliance based on investigator judgement
Clinical trial NCT00482430 (phase 2, status: completed)
Conditions: paranoid schizophrenia, schizophrenia
ICD codes: F20.0, F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: mk0557, comparator: placebo (unspecified)
SMILES: FC1=C(C=CC=C1)N1C=CC(NC(=O)[C@H]2CC[C@@]3(CC2)OC(=O)C2=C3C=NC=C2)=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is clinically stable, on current antipsychotic medication for at least 3
             months and current dose for 2 months

          -  Patient has a 6th grade reading level or better and has completed at least 6 years of
             formal education

          -  Females are not pregnant, and those who can have children agree to remain abstinent or
             use acceptable birth control throughout study

          -  Patient has had a stable living arrangement for at least 3 months prior to study start

          -  Patient is in general good health based on screening assessments

        Exclusion Criteria:

          -  Patient has a major disease/disorder that may interfere with cognitive testing (such
             as mental retardation) and/or pose a risk upon study participation

          -  Patient has a history of head trauma with loss of consciousness greater than 15
             minutes

          -  Patient has had warfarin treatment, MAO inhibitors, clonazepam, clozapine or St.
             John's wort within 1 month of screening

          -  Patient has had ECT treatment within 6 months of screening

          -  Patient requires treatment with antihistamines or certain other medications listed in
             the protocol

          -  Patient has a history of liver disease that has been active within the last 2 years,
             or a history of cancer within past 5 years

          -  Patient has a history of alcohol or drug dependence within past year or alcohol or
             drug abuse within 3 months of screening
Clinical trial NCT00329693 (phase 2, status: completed)
Conditions: ovarian hyperstimulation syndrome
ICD codes: N98.1
Drugs: norprolac, norprolac, norprolac, norprolac
SMILES: [H][C@]12C[C@@H](CN(CCC)[C@]1([H])CC1=CC=CC(O)=C1C2)NS(=O)(=O)N(CC)CC, [H][C@]12C[C@@H](CN(CCC)[C@]1([H])CC1=CC=CC(O)=C1C2)NS(=O)(=O)N(CC)CC, [H][C@]12C[C@@H](CN(CCC)[C@]1([H])CC1=CC=CC(O)=C1C2)NS(=O)(=O)N(CC)CC, [H][C@]12C[C@@H](CN(CCC)[C@]1([H])CC1=CC=CC(O)=C1C2)NS(=O)(=O)N(CC)CC
Eligibility criteria:

        Inclusion Criteria

          1. Signed Informed Consent Form, prior to screening evaluations

          2. In good physical and mental health

          3. Pre-menopausal females between the ages of 21-37 years (both inclusive) at the time of
             randomisation

          4. Infertility for at least 1 year before randomisation, except for proven bilateral
             tubal infertility

        Exclusion Criteria

          1. Any clinically significant systemic disease

          2. Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)

          3. History of recurrent miscarriage

          4. Undiagnosed vaginal bleeding
Clinical trial NCT00713518 (phase 2, status: completed)
Conditions: age related macular degeneration
ICD codes: H35.3130, H35.3230, H35.3110, H35.3120, H35.3131, H35.3132, H35.3190
Drugs: 0.5 mg ranibizumab, 3 mg pf-04523655, 1 mg pf-04523655
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females age 50 years or older with active primary or recurrent subfoveal
             choroidal neovascularization (CNV) secondary to age-related macular degeneration
             (AMD). Active CNV is defined as any leakage detected on FFA or OCT. Note: Female
             subjects 50- 60 years of age must be amenorrheic for at least 2 years and have a serum
             FSH level within the laboratory reference range for postmenopausal women

          -  The total area of CNV (including both classic and occult components) encompassed
             within the lesion must be 50% or more of the total lesion area.

          -  The total lesion size ≤12 disc areas.

          -  Best corrected visual acuity using ETDRS protocol of 20/40 to 20/320 (letter score
             ≤73) in the study eye at the screening visit.

          -  Best corrected visual acuity score in the fellow eye of 20/400 or better (letter score
             of ≥19) at the Screening Visit. Note: Only one eye will be treated (study eye) through
             the duration of the study. In the event both eyes are eligible for study entry the
             study eye should be selected by the investigator and subject. The non-study eye may be
             treated with an approved AMD therapy

          -  Subject has retinal central subfield thickness ≥250µm measured using Stratus OCT.

        Exclusion Criteria:

          -  Prior treatment with verteporfin photodynamic therapy, external-beam radiation
             therapy, or transpupillary thermotherapy in the study eye

          -  Previous subfoveal focal laser photocoagulation in the study eye

          -  Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month
             preceding Baseline

          -  History of vitrectomy, submacular surgery or other surgical intervention for AMD in
             the study eye

          -  Previous participation in any studies with investigational drugs or treatments
             administered 1 month preceding Baseline visit such as systemic glucocorticoids, ocular
             or periocular steroids (eg, triamcinolone, anecortave acetate), anti-angiogenic drugs
             such as pegaptanib (Macugen), ranibizumab (Lucentis), bevacizumab (Avastin) in the
             study eye

          -  Subretinal hemorrhage in the study eye that involves the fovea, if the size of the
             hemorrhage is either 50% or more of the total lesion area or 1 or more disc areas in
             size

          -  CNV in either eye of other etiology, eg, ocular histoplasmosis, trauma, or pathologic
             myopia

          -  Presence of subfoveal scarring

          -  Retinal pigment epithelial tear involving the macula in the study eye
Clinical trial NCT01261572 (phase 2, status: completed)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: degarelix
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven prostate cancer (adenocarcinoma) of all stages

          -  A patient in whom endocrine treatment is indicated. Patients with rising serum PSA
             after having prostatectomy or radiotherapy performed with curative intention

          -  Serum testosterone level above 2.2 ng/mL

          -  An ECOG (Eastern Co-operative Oncology Group) P.S. (Performance Status) score of 0 to
             2

          -  Serum PSA level above 2 ng/mL

        Exclusion Criteria:

          -  Previous or present endocrine treatment for prostate cancer.

        However, patients who have undergone neoadjuvant/adjuvant endocrine therapy for a maximal
        duration of 6 months and in whom prostatectomy or radiotherapy was terminated at least 6
        months

          -  Treated with a 5α-reductase inhibitor

          -  A candidate for curative therapy, i.e., radical prostatectomy or radiotherapy within
             12 months

          -  Concurrent or a history of severe liver disease

          -  Abnormal ECG such as long QTc

          -  A patient receiving ASP3550 in past times

          -  Administered drug in another clinical study or a post-market clinical study in the 28
             days prior to the study